Appclon 'AT101', "Complete Remission Confirmed in 75% of Phase 1 Clinical Trial Patients"

Abclon's chimeric antigen receptor (CAR)-T blood cancer treatment 'AT101' has increased the complete remission (CR) rate to 75% in Phase 1 clinical trials.

Yoon Deok-hyun, Director of the CAR-T Center at Asan Medical Center Cancer Hospital in Seoul, is presenting the Phase 1 clinical trial results of Abclon's CAR-T therapy 'AT101' at the 2023 International Conference of the Korean Society for Hematopoietic Stem Cell Transplantation (ICBMT 2023) held on the 1st.
[Photo by Abclon]

Abclon announced on the 4th that it presented an update on these Phase 1 clinical trial results at the 2023 International Conference on Blood and Marrow Transplantation (ICBMT 2023) held on the 1st. The presentation was conducted by Deokhyun Yoon, director of the CAR-T Center at the Asan Medical Center Cancer Hospital in Seoul, who led the AT101 clinical trials. This update includes follow-up observation results after patient administration, in addition to the data presented at the American Society of Clinical Oncology (ASCO) in June.

AT101 is an anticancer agent applying a novel humanized antibody different from existing CAR-T therapies. The Phase 1 trial is being conducted on a total of 12 patients divided into low-dose (6 patients), medium-dose (3 patients), and high-dose (3 patients) groups.

According to Abclon, one patient in the high-dose group converted from partial remission (PR) to CR, achieving a 100% complete remission rate in both the medium- and high-dose groups. With CR confirmed in a total of 9 patients including 3 from the low-dose group, the overall complete remission rate among all trial participants rose to 75%.

Among the low-dose group patients who passed more than one year after administration, all three CR patients have maintained CR, showing encouraging results in terms of the durability of the treatment effect. While existing CAR-T therapies show increased relapse rates at 6 months compared to 3 months post-treatment, AT101 has maintained complete remission so far, raising expectations for long-term treatment efficacy.

An Abclon representative stated, "AT101 demonstrates outstanding results not only in high treatment efficacy and safety but also in the durability of the treatment effect," adding, "We plan to smoothly proceed with Phase 2 clinical trials and continuously update the results of Phase 1."

This content was produced with the assistance of AI translation services.